New Issue: Hana Biosciences to raise $14.8 million from private placement of stock

By Sheri Kasprzak

New York, Oct. 19 - Hana Biosciences Inc. said it received definitive agreements from institutional investors for its $14.8 million private placement.

The company plans to sell 3.7 million shares at $4.00 each by Oct. 21 to a number of institutional investors, including ProMed Management, Lehman Brothers, Pogue Capital Management, Perceptive Life Sciences Fund, Atlas Equity, Mosaix Ventures, Coqui Capital and Panacea Asset Management.

Oppenheimer & Co. Inc. is the bookrunner with Griffin Securities as a placement agent.

San Francisco-based Hana is a biopharmaceutical company focused on cancer treatments.

Issuer:	Hana Biosciences Inc.
Issue:	Stock
Amount:	$14.8 million
Shares:	3.7 million
Price:	$4.00
Warrants:	No
Placement agents:	Oppenheimer & Co. Inc. (lead), Griffin Securities
Investors:	ProMed Management, Lehman Brothers, Pogue Capital Management, Perceptive Life Sciences Fund, Atlas Equity, Mosaix Ventures, Coqui Capital, Panacea Asset Management
Announcement date;	Oct. 19
Settlement date:	Oct. 21
Stock price:	$4.43 at close Oct. 19

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.